An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer

Trial Profile

An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Everolimus (Primary) ; Letrozole (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms BOLERO-4
  • Sponsors Novare Pharmaceuticals; Novartis
  • Most Recent Events

    • 12 Sep 2017 Results (n=202, data cut off 17 December 2016) of analysis comparing progression free survival in subgroups with overall population presented at the 42nd European Society for Medical Oncology Congress
    • 30 Jun 2017 Planned End Date changed from 21 Apr 2020 to 22 Jun 2020.
    • 30 Jun 2017 Planned primary completion date changed from 21 Apr 2020 to 22 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top